Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Paola Rogliani (Rome, Italy), Paola Rogliani, Josuel Ora, Luigino Calzetta, Gabriella Lucà, Maria Gabriella Matera, Mario Cazzola. Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation. Eur Respir J 2016; 48: Suppl. 60, 5062

Member's Comments

No comment yet.

Related content which might interest you: The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 Anti-inflammatory effects of the novel phosphodiesterase type 4 inhibitor CHF6001 on COPD alveolar macrophages and lung tissue Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 The anti-proliferative effect of hydrogen sulfide upon human airway smooth muscle in COPD Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 The novel compound Sul-121 inhibits inflammation in experimental models of chronic obstructive pulmonary disease Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Inhaled beta-agonist does not modify sympathetic activity in patients with COPD Source: International Congress 2014 – Multidimensional analysis of respiratory problems Year: 2014 Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model) Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Pharmacologic bronchodilation response to salbutamol in COPD patients Source: International Congress 2014 – Predictors Year: 2014 Monitoring catalase activity in COPD exacerbations Source: International Congress 2016 – Airway biomarkers Year: 2016 Effect of different inhalation methods on the airway clearance in moderate and severe AECOPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Pharmacological characterization of the protective effect of benralizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 Inhaled vilanterol trifenatate/fluticasone furoate increases maximum diaphragm contraction in severe COPD Source: International Congress 2014 – Clinical physiology and respiratory muscles Year: 2014